https://www.selleckchem.com/pr....oducts/cobimetinib-g
Other aspects of management focus on supportive care aimed at minimizing the risk of bleeding, via transfusion of blood products. The use of blood products is more liberal in APL, due to the hemorrhagic phenotype and unacceptably high rates of early hemorrhagic death. This review will focus on the pathophysiology, risk factors, clinical implications, and the management of DIC in patients across the spectrum of acute leukemias.Platelet disorders comprise heterogeneous diseases featured by reduced platelet counts and/o
Like
Comment
Share
